EGFR and non-small cell lung carcinoma: The development and the use of three generations of EGFR inhibitors in the clinical setting significantly improved the prognosis of NSCLC cancer patients, in particular in ~10% to 15% of cases of white patients and even 50% of cases of Asian NSCLC patient, harboring activating EGFR mutations [104].